Abstract
The major findings of the LHS that have been reported thus far are that an effective smoking cessation program can be developed that can produce more than a 20% success rate in getting smokers to give up the habit permanently, and that by stopping smoking, individuals with early COPD benefit by having an initial improvement in lung function and a slowing of the annual loss of their FEV1. The use of a bronchodilator has a short-term effect in improving the FEV1, but it does not affect long-term changes in lung function. AHR is common in patients with mild-to-moderate COPD. The reward for a smoker to give up the habit is an initial gain in FEV1 and a subsequent close to normal annual rate of decline of this pulmonary function parameter. These results should provide a positive incentive for smokers to quit and thereby decrease the morbidity and mortality caused by the use of tobacco.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 523-547 |
| Number of pages | 25 |
| Journal | Medical Clinics of North America |
| Volume | 80 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1996 |
Bibliographical note
Funding Information:Supported by Contract NO1-HR-46014 from the Division of Lung Diseases of the National Heart, Lung and Blood Institute.
Funding Information:
The Salt Lake City Center has been assisted by the Clinical Research Center, Public Health Research Grant MO1-RR00064 from the National Center for Research Resources.